Intellia Therapeutics (NTLA) Equity Ratio: 2015-2025
Historic Equity Ratio for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to 0.81.
- Intellia Therapeutics' Equity Ratio fell 1.41% to 0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81, marking a year-over-year decrease of 1.41%. This contributed to the annual value of 0.73 for FY2024, which is 9.30% down from last year.
- Per Intellia Therapeutics' latest filing, its Equity Ratio stood at 0.81 for Q3 2025, which was up 1.65% from 0.80 recorded in Q2 2025.
- Intellia Therapeutics' 5-year Equity Ratio high stood at 0.84 for Q1 2023, and its period low was 0.73 during Q4 2024.
- Its 3-year average for Equity Ratio is 0.81, with a median of 0.81 in 2024.
- As far as peak fluctuations go, Intellia Therapeutics' Equity Ratio climbed by 15.37% in 2021, and later dropped by 9.30% in 2024.
- Over the past 5 years, Intellia Therapeutics' Equity Ratio (Quarterly) stood at 0.80 in 2021, then grew by 1.15% to 0.81 in 2022, then fell by 0.69% to 0.81 in 2023, then decreased by 9.30% to 0.73 in 2024, then dropped by 1.41% to 0.81 in 2025.
- Its Equity Ratio stands at 0.81 for Q3 2025, versus 0.80 for Q2 2025 and 0.79 for Q1 2025.